• Keine Ergebnisse gefunden

Risedronate and the risk of oesophageal cancer (use in patients with Barrett’s oesophagus) Final SmPC and PL wording agreed by PhVWP in August 2012

N/A
N/A
Protected

Academic year: 2022

Aktie "Risedronate and the risk of oesophageal cancer (use in patients with Barrett’s oesophagus) Final SmPC and PL wording agreed by PhVWP in August 2012"

Copied!
1
0
0

Wird geladen.... (Jetzt Volltext ansehen)

Volltext

(1)

Risedronate and the risk of oesophageal cancer

(use in patients with Barrett’s oesophagus) September 2012 Page 1/1

Risedronate and the risk of oesophageal cancer (use in patients with Barrett’s oesophagus)

Final SmPC and PL wording agreed by PhVWP in August 2012

Doc.Ref.: CMDh/PhVWP/059/2012 September 2012

(Additions are in bold)

SUMMARY OF PRODUCT CHARACTERISTICS

Section 4.4 Special warnings and precautions for use

Caution should be used

• If risedronate is given to patients with active or recent oesophageal or upper gastrointestinal problems (including known Barrett's oesophagus).

PACKAGE LEAFLET

Under Section 2 ‘BEFORE YOU TAKE YOUR MEDICINE’

Take special care and talk to your doctor BEFORE you start taking <Risedronate>

If you have had problems in the past with your oesophagus (the tube that connects your mouth with your stomach). For instance you may have had pain or difficulty in swallowing food or you have previously been told that you have Barrett's oesophagus (a condition associated with changes in the cells that line the lower oesophagus)

Referenzen

ÄHNLICHE DOKUMENTE

☛ As long as you are a minor (less than 18 years old) and have an Aufenthaltserlaubnis acording to the new residence right regulations (§ 25a Aufenthaltsgesetz), your parents and

You have been asked to create a going green leaflet for English-speaking tourists who come to visit your area.. In your leaflet

An Austrian Facebook friend just told me about his school — a technical college for ‘materials engineering’ or something like that.. He told me that a lot of Austrian teenagers

“Concomitant therapeutic use of tramadol and serotonergic drugs, such as selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors

 If you were born with or have had any condition with abnormal heart rhythm (seen on ECG, electrical recording of the heart), have salt imbalance in the blood (especially

pregnancy register and the North American Antiepileptic Drug (NAAED) pregnancy registry indicate that infants exposed to topiramate monotherapy in the first trimester have

Rosuvastatin (Crestor) and March 2012 Page 1 of 1 risk of gynaecomastia. Rosuvastatin (Crestor) and risk

Cases of QT interval prolongation and ventricular arrhythmia including torsade de pointes have been reported during the post-marketing period, predominantly in patients of